Clinical risk is product risk in context
DCB 0129 asks manufacturers to manage clinical risk for health IT products used in care settings. It is not just a document. It is a way of connecting product behaviour to potential clinical harm.
For software teams, this means safety evidence must connect to user journeys, failure modes, mitigations, release control and post-market feedback.
Evidence should connect the story
Technical, clinical, risk, software, security and governance evidence should reinforce the same route-to-market story. When these artefacts are built separately, the file becomes harder to defend and harder to reuse.
A strong evidence plan makes regulatory review, buyer assurance and future expansion easier because it shows why the product is safe, effective, controlled and trustworthy.
What good looks like
A credible clinical safety file shows hazards, causes, controls, residual risk and ownership. It also shows how the product team learns from incidents, changes and real-world use.
That makes it valuable beyond NHS assurance: it improves product judgment.
Clinical safety begins with the clinical workflow
DCB 0129 cannot be understood properly from the product screen alone. The key question is how the technology is used in a care pathway, who relies on it, what assumptions it creates and what harm could occur if it fails or is misunderstood.
That makes clinical safety a product design discipline. The hazard log should not feel detached from user stories, release notes and clinical feedback. It should help the product team make better decisions about risk, communication and control.
The Clinical Safety Officer role needs real authority
A named Clinical Safety Officer is not a ceremonial requirement. The CSO needs enough context, access and authority to challenge product decisions where clinical risk is not controlled. For startups, that role may be external, but it still needs to be integrated into the operating model.
The most useful CSO input happens early: reviewing intended use, identifying foreseeable hazards, shaping mitigations and checking that safety evidence keeps pace with product change.
The safety case should explain why the product is acceptable to use
A credible clinical safety case does more than list hazards. It explains why residual risk is acceptable in the intended context, how controls are implemented, what evidence supports them and how the manufacturer will learn from use.
This is valuable for NHS assurance, but it is also valuable commercially. It helps clinical buyers, partners and internal teams understand the product’s safety logic without hunting through disconnected documents.
Connect DCB 0129 to DTAC and product governance
DCB 0129 often sits inside a broader NHS readiness story. It should connect to DTAC, data protection, security, usability, accessibility, support and post-market monitoring. If those workstreams are separate, the same risk may be described differently in multiple places.
Neural Vibe helps manufacturers make clinical safety part of the route-to-market plan, not a late document request. That turns assurance into a practical product control system.